Skip to content
Review

Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.

Aug 2026 · Nature reviews: Gastroenterology & hepatology · 0 citations · 99 references
Medicine

TL;DR

Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.

View source

Similar papers

Review Open access Sep 2026

The global burden of metabolic and alcohol-associated liver disease (MetALD)

Chronic liver disease is a leading cause of global morbidity and mortality, with an evolving etiologic landscape driven by rising metabolic dysfunction and persistent alcohol use. The introduction of metabolic and alcohol-associated liver disease (MetALD) recognizes the coexistence of these exposures as dual drivers of...

Gurmehr Brar, Brian P. Lee · 0 citations
Review Open access Aug 2026

Effects of diabetes, obesity, and metabolic syndrome on alcohol-associated liver disease: A systematic review

Background: Alcohol-associated liver disease (ALD) is a leading cause of advanced liver disease and liver transplantation worldwide. Cardiometabolic risk factors (CMRFs) may worsen ALD prognosis. While recent nomenclature acknowledges the impact of CMRFs in steatotic liver disease with low-to-moderate alcohol use, indi...

Dhiraj K Peddu, Vitchapong Prasitsumrit, Matthew Kubina et al. · 0 citations
Open access Oct 2026

The Association Between Alcohol Intake and Incident Major Adverse Liver Outcomes Remains Stable Despite Rising Metabolic Risk

The association between alcohol intake and MALOs remained stable over time despite increasing metabolic burden, suggesting that increasing metabolic burden has not modified the association between alcohol intake and liver outcomes at the population level.

Eneli Katunin, V. Männistö, F. Åberg · 0 citations
Review Open access Sep 2026

MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management

Metabolic dysfunction-associated steatotic liver disease with increased alcohol consumption (MetALD) is a newly defined category within the spectrum of steatotic liver disease. It captures patients who have both cardiometabolic risk factors and alcohol intake above the thresholds accepted for metabolic dysfunction-asso...

Hubert Krzewiński, Oliwier Wątroba, Jarosław Koza · 0 citations
Review Open access Sep 2026

Causal relationship between liver fat reduction and clinical outcomes in human genetic studies and randomized clinical trials of metabolic-dysfunction associated steatohepatitis

The largest-to-date genome-wide association study of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions a...

N. Verweij, G. Hindy, Q. Nguyen et al. · 0 citations
Review Open access Aug 2026

Alcohol-Aware Risk Stratification and Subtype-Specific Care Pathways Across MASLD, MetALD, and ALD.

Accurate classification and risk stratification across metabolic dysfunction-associated steatotic liver disease (MASLD), MetALD, and alcohol-associated liver disease (ALD) depend critically on the assessment of alcohol exposure. However, current clinical practice relies largely on self-reported alcohol intake, which ma...

Hyo Young Lee, E. Yoon, D. Jun · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.